This section provides a patient-friendly summary of the main symptom domains and therapeutic benefits of Sodium Valproate Wockhardt.

---

Main Uses: Symptoms and Therapeutic Benefits

This medication is applied across domains where additional symptomatic support is needed. It is commonly used to help with epilepsy and various seizure disorders, acute manic episodes associated with Bipolar Disorder, and the prophylactic treatment for recurrent migraine headaches.

For seizure disorders, the medicine helps address symptom clusters that may become intense or disruptive, such as generalized onset seizures and complex partial seizures. The treatment plays a role in managing symptoms related to the reduction in seizure frequency and severity, which contributes significantly to patient comfort by assisting with maintaining functional stability. For mood, it supports patients during episodes of heightened discomfort by easing distress and helping to control symptoms related to heightened physiological activity, such as extreme overactivity.

“It is a relevant therapeutic option for easing symptoms that create noticeable interference with daily comfort and stability.”

Applied in scenarios where short-term symptom management is important, the medicine plays a role in managing conditions involving episodic or fluctuating manifestations. It is commonly used to help with complex symptom patterns in both adults and children.

Contextual Note on Symptom Management The primary support provided is to help maintain a sense of stability during symptomatic periods, and may assist with the reduction in the recurrence of epileptic fits, manic flares, or debilitating migraine attacks.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Scope

Populations for whom use is contraindicated: Use is absolutely prohibited for patients with active liver disease or significant hepatic dysfunction, Urea Cycle Disorders (UCD), or known Mitochondrial Disorders (e.g., POLG gene mutations). It is also contraindicated for patients with Porphyria or known hypersensitivity to the medicine.

Pregnancy and Lactation Eligibility Status: Sodium Valproate Wockhardt is contraindicated for all uses in pregnant women, except for epilepsy if no suitable alternative treatment exists. For Women of Childbearing Potential (WOCBP), use is contraindicated unless the conditions of a comprehensive Pregnancy Prevention Programme (PPP) are strictly met. New male and female patients under the age of 55 must not be initiated on this medicine unless two specialists independently agree that no other effective treatment is available, as required by updated regulatory guidance.

Age-Related and Condition-Specific Rules: Children under two years of age carry the highest risk of fatal hepatotoxicity. In the geriatric population, the regulatory label requires a reduced starting dose and slower dose increase. Use is not recommended in patients with mild to moderate hepatic impairment.

Regulatory Classification: Official classifications defining eligibility include Contraindicated, Not Recommended, and Use under Conditional Program (PPP), establishing strict population boundaries based on organ function, age, and reproductive status.

The official regulatory profile for Sodium Valproate defines key pharmacokinetic and pharmacodynamic constraints with other medicines and products.

Pharmacokinetic (PK) Modulation

Co-administration with enzyme-inducing medicinal products, such as Phenytoin or Carbamazepine, is documented to increase Valproate clearance, potentially lowering plasma concentrations. Conversely, enzyme-inhibiting medicines, like Felbamate, decrease Valproate clearance. Valproate can also affect the exposure of other medicines (e.g., Lamotrigine) by inhibiting their metabolism or via protein binding displacement. Aspirin is documented to increase the free, active fraction of Valproate through plasma protein binding competition. Additionally, Estrogen-containing hormonal contraceptives may increase Valproate clearance.

Interaction-Related Restrictions

A clinically significant restriction involves Carbapenem antibiotics, which are known to rapidly reduce Valproate plasma levels to sub-therapeutic concentrations. The co-administration of Valproate with Topiramate carries the specific toxicodynamic risk of hyperammonemia and hypothermia, as noted in regulatory labeling. Furthermore, co-use with other central nervous system depressants, including certain antipsychotics and antidepressants, may result in potentiated sedation. Certain interaction risks, such as the sedation caused by Phenobarbital, are noted to be more pronounced in the pediatric population.

The action of Sodium Valproate is rooted in a multi-modal mechanism that modulates pathways that govern neuronal stability by simultaneously influencing neurochemical, electrical, and long-term regulatory processes within the central nervous system.

Boosting CNS Inhibitory Signals

This domain involves the enzyme GABA-Transaminase (GABA-T). By inhibiting this enzyme, the medicine prevents the breakdown of the inhibitory neurotransmitter GABA, leading to sustained higher concentrations in the synapse. This ultimately increases the brain's overall inhibitory tone, thereby limiting excitatory activity in relevant pathways.

Stabilizing Neuronal Excitability

Sodium Valproate directly interacts with voltage-gated ion channels—specifically, VNa and TCa channels. By blocking these channels, the drug physically limits the neuron's ability to propagate rapid, high-frequency electrical signals and interferes with the rhythmic firing patterns. This action lowers the potential for nerve cell excitability, limiting the propagation of high-frequency electrical signals.

Long-Term Modulation of Cellular Resilience

A distinct mechanism involves the inhibition of Histone Deacetylase (HDAC). This action modulates gene transcription, leading to altered expression of neuro-regulatory proteins over time. This influences pathways governing neuronal regulation and promotes transcription of regulatory proteins, modulating neurobiological processes over time.

Official Administration Guidelines

Sodium Valproate Wockhardt is authorized for use via two primary methods: Oral administration for long-term maintenance and Intravenous (IV) administration for temporary substitution when oral intake is not feasible. The oral forms, which include immediate- and extended-release tablets, must be swallowed whole and must not be crushed or chewed to preserve the medication's designed release characteristics. The oral solution, conversely, may be mixed with cold, non-carbonated food or drink for intake.

Dosing is always initiated using a gradual dose escalation (titration) protocol, starting typically between 10 to 15 mg/kg/day for epilepsy. Doses are slowly increased over time, aiming for a maintenance range that often falls between 1000 mg and 2000 mg daily, with the maximum dose generally not exceeding 60 mg/kg/day. Frequency of intake depends on the formulation: extended-release tablets are typically given once daily, while immediate-release forms may require divided daily doses.

Procedural Constraints

IV administration is a short-term measure and is procedurally constrained, usually not exceeding 14 days, requiring a transition to oral forms as soon as feasible. Older adults must start with a lower dose, and the titration schedule must proceed more slowly. If a dose is missed, the next dose should not be doubled, maintaining the continuity of the prescribed schedule. These guidelines collectively define the standardized use protocol.

Research evidence / Overview of Studies for Sodium Valproate Wockhardt

Evidence for Use in Epilepsy and Seizure Disorders

Research has focused on using short-term Randomized Controlled Trials (RCTs) and long-term observational cohort studies to evaluate Valproate in individuals with epilepsy. The studies monitored outcomes related to functional balance, primarily focusing on the reduction in the frequency of seizures and the proportion of people who achieved a specific seizure-free status during the observation period. This evidence was collected across various populations, including adults, adolescents, and children, and for conditions characterized by episodic changes, such as generalized onset seizures. The data show patterns related to measured outcomes for seizure control over the short-term duration of controlled trials. Current regulatory summaries and systematic reviews note that evidence is limited for comparisons against all newer medications now available for epilepsy.

Evidence for Use in Acute Manic Episodes in Bipolar Disorder

The research structure for acute manic episodes is centered on short-term, placebo-controlled, and active-comparator RCTs. These studies were designed to evaluate outcomes related to episodic changes. Researchers primarily used validated functional scales to measure changes in the severity of manic symptoms during the initial few weeks of treatment. Studies monitored changes measured during the study period, reporting patterns in symptom scores compared to a placebo. Comparative trials reported on differences and similarities between outcomes measured for Valproate and those observed for other mood-stabilizing agents, such as lithium.

Evidence for Migraine Prophylaxis

Sodium Valproate was studied for the preventive management of recurrent migraine headaches. The evidence primarily comes from placebo-controlled trials in adult populations. Research examined outcomes related to physical discomfort, specifically monitoring the reduction in the monthly frequency of migraine attacks. Studies reported measurements where the observed attack frequency showed specific patterns of change for participants receiving Valproate compared to those receiving placebo. Evidence for the use of Valproate in patients with chronic migraine or those experiencing medication overuse headache remains insufficient or not fully established.

Research Gaps and Areas of Uncertainty for Sodium Valproate

Several key limitations have been noted in the research landscape: Follow-up durations were limited in many core trials for acute conditions, meaning long-term outcomes are not well characterized. Evidence quality varies across studies, particularly for certain populations where data are still emerging and certainty remains low. Studies help show what has been observed so far, but more research is ongoing to fill these identified gaps.

Key Studies & References

1. Valproate for acute manic episodes in bipolar disorder: a systematic review of randomized controlled trials
2. Seizures and epilepsy in over 5s: diagnosis and management (NICE Guideline NG217)

Common questions about Sodium Valproate Wockhardt (FAQ)

---

Q: Is Sodium Valproate Wockhardt the same as valproic acid?

Sodium Valproate is closely related to valproic acid. Regulatory documents classify Sodium Valproate as a salt form of the medicine's active component, which is the valproate ion. Both forms are designed to deliver this active component and work through the same regulatory mechanism in the body.

Q: What common supplements or vitamins might interact with this medicine?

Official guidance indicates that patients should be mindful of potential interactions with herbal products. Additionally, for women of childbearing potential, regulatory guidance recommends that folic acid be routinely taken alongside the medicine. This recommendation relates to the known risk of major congenital malformations associated with valproate.

Q: Can I drink alcohol if I am taking Sodium Valproate Wockhardt?

Official guidance notes that consuming alcohol can intensify some of the drug's effects, such as tiredness or sleepiness. Official guidance suggests that patients should be mindful of how the medicine affects them before consuming alcohol.

Q: How often do people usually need blood tests while on this treatment?

Regulatory information states that blood tests, such as liver function tests, should be performed prior to therapy and at frequent intervals thereafter. Particular monitoring is required during the first six months of treatment when the risk of serious liver toxicity is highest.

Q: What is the difference between Sodium Valproate and valproate semisodium?

Sodium Valproate and Valproate Semisodium (often called Divalproex Sodium) are both chemically related salt forms of the active valproate component. They are typically used in different oral formulations, such as extended-release tablets, which are designed to improve patient tolerance and absorption.

Q: Why is folic acid sometimes mentioned alongside valproate treatment?

Regulatory guidance for women of childbearing potential taking valproate for epilepsy includes the recommendation that folic acid should routinely be taken. This is related to the known risk of major congenital malformations associated with the use of the medicine.

Q: Is it normal to feel tired or dizzy when first starting Sodium Valproate Wockhardt?

Tiredness (somnolence) and dizziness are classified in official regulatory documents as Very Common or Common side effects. This indicates they are frequently reported by patients, particularly when first starting treatment.

Q: Why is the drug sometimes prescribed as a modified-release tablet?

Modified-release or extended-release formulations are described as providing a controlled release of the medicine over time. This design is typically intended to allow for once-daily dosing, which can simplify the administration schedule.

Q: What are the different strengths or dosages this medicine comes in?

According to the official product information, Sodium Valproate is available in multiple dosage forms and strengths. These include oral tablets (often in 200 mg and 500 mg strengths), oral solutions, and formulations for intravenous (IV) injection.

Q: What does the term 'valproate' actually mean?

The term 'valproate' refers to the active component (the valproate ion) of the medicine. It is a chemical derivative of Valeric Acid, a short-chain fatty acid. This is the chemical form that is designed to stabilize neurological function in the body.

Q: What happens if I forget to take a dose?

Regulatory information specifies that a double dose should not be taken to make up for a missed one. The precise action (whether to take the forgotten dose or skip it entirely) depends on how close it is to the next scheduled dose.

Q: Are there any common foods or drinks that interact with Sodium Valproate Wockhardt?

Official information states that aside from the specific caution noted with alcohol, patients can generally eat and drink normally while using this medicine. There are no blanket restrictions on common foods or non-alcoholic drinks.

Q: Does this medicine cause weight gain?

Weight gain is listed in official regulatory documents as a Common side effect. This classification means it is reported in approximately 1% to 10% of people receiving the medicine.

Q: Is hair loss a possible side effect of Sodium Valproate Wockhardt?

Yes, hair loss is listed in official regulatory documents as a potential adverse reaction associated with the use of this medicine.

Q: Can Sodium Valproate Wockhardt affect sleep patterns?

Official regulatory documents list several central nervous system effects. These include somnolence (drowsiness) and, in some cases, changes in sleep patterns as potential adverse reactions.

Q: Are there any long-term effects of taking Sodium Valproate Wockhardt?

Official research summaries acknowledge that while the effects of the medicine are described for short-term outcomes, the follow-up duration in many core trials was limited. This indicates that long-term outcomes are not fully characterized by those studies.

Q: Does Sodium Valproate Wockhardt interact with birth control pills?

Regulatory documents state that Estrogen-containing hormonal contraceptives may increase the clearance of valproate from the body. This could potentially lower the concentration of the medicine in the blood.

Q: Is there a generic version of Sodium Valproate Wockhardt?

Yes, the active ingredient, Valproate, is widely available in generic formulations. These are typically supplied under the official chemical name, such as Sodium Valproate or Valproic Acid.

Q: Do different brands of Sodium Valproate work exactly the same way?

Official regulatory guidelines require that generic formulations of the medicine demonstrate bioequivalence to the originator product. This means they must show a similar rate and extent of absorption into the body to be approved.

Q: Can men taking Sodium Valproate Wockhardt have children safely?

Regulatory safety information acknowledges concerns regarding a potential link between valproate use and impaired male fertility and associated risks to children. The guidance may include a requirement for contraception and a defined period of waiting before attempting to conceive.

Q: Does Sodium Valproate Wockhardt need to be taken with food?

Regulatory guidance states that the medicine can be taken with or without food. Taking it with food may be suggested to help reduce some common gastrointestinal side effects.

Q: What is therapeutic drug monitoring and why is it done for valproate?

Therapeutic Drug Monitoring (TDM) involves measuring the concentration of valproate in the blood. This process helps ensure the level is within a defined therapeutic range (e.g., 50 to 100 mu g/mL total valproate) and to identify potential toxicity risks.

Q: How is Sodium Valproate Wockhardt generally stopped or discontinued?

Regulatory guidance states that the abrupt discontinuation of the medicine is associated with risks such as withdrawal symptoms and increased seizure frequency. Regulatory guidance indicates that the medicine is generally gradually tapered off under specialist supervision.

Q: Are there any known issues with driving or operating machinery while taking it?

Regulatory warnings state that this medicine may affect the ability to drive or operate machinery due to potential side effects such as drowsiness and dizziness. Official warnings state that a person should be aware of how the medicine affects them before engaging in these activities.

Q: Why is Sodium Valproate sometimes used for mood stabilization?

Official regulatory classifications include the use of valproate for the treatment of Acute Manic Episodes in Bipolar Disorder. This is the clinical context for why it is often referred to as a mood stabilizer.

Q: Are there specific patient groups who are more likely to get side effects?

Yes, regulatory documents note that pediatric patients (especially those under two years of age) have a higher risk of fatal liver toxicity. Additionally, older adults may be more sensitive to side effects like drowsiness, which requires specific dose adjustments.

Q: Is the medication effective for all types of seizures?

Regulatory indications show that the medicine is listed for a broad spectrum of seizure types. This includes generalized onset seizures, complex partial seizures, and simple or complex absence seizures.

Q: What does official research say about the long-term effectiveness of valproate?

Official research summaries indicate that while the effects of the medicine are described for short-term outcomes, follow-up durations in many core trials was limited. This means long-term outcomes are not fully characterized by those studies.

Q: What is the risk of overdose with Sodium Valproate Wockhardt?

Regulatory documents list the potential effects of an overdose, which typically involve deep sedation (coma or somnolence), muscular weakness, and disturbances to the body's metabolism.

Q: Does this medication have any effect on bone health?

Regulatory and long-term safety reviews of anticonvulsants, including valproate, have examined an association between their use and potential effects on bone health, such as a possible risk of decreased bone density.

Q: Is Sodium Valproate Wockhardt associated with any changes in appetite?

Changes in appetite are sometimes reported as a side effect. The medicine is officially classified as commonly being associated with weight gain, which may be related to changes in appetite.

Q: Can Sodium Valproate Wockhardt cause agitation or changes in behavior?

The official label documents include a warning of an increased risk of Suicidal Behavior and Ideation. Other adverse reactions, such as changes in mood or feeling anxious, are also listed.

Storage and Disposal Requirements

The official labeled requirements for Sodium Valproate Wockhardt govern how the medicine must be preserved and ultimately discarded to maintain product stability and ensure environmental safety.

Storage Condition	Requirement
Temperature and Light	Store the product below 25 C and protect from light.
Container Rule	Keep the medicine in its original container and ensure the bottle is tightly closed (for oral solution).
Child Safety	Keep out of the sight and reach of children at all times.
Disposal Rule	Dispose of unused or expired product in accordance with local requirements.

The regulatory profile explicitly directs that the product must not be exposed to heat and should remain in its original, tightly sealed packaging. Furthermore, medicines should not be thrown away via household waste or wastewater, requiring return to a pharmacy or disposal via authorized local channels.